Psyence Biomedical (PBM)
Developing nature-derived psilocybin-assisted psychotherapy for adjustment disorder after cancer.
Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform
MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) technologies, has been selected to support the administration of Scripius' commercial, Medicare, and Medicaid pharmacy benefit programs. Through this collaboration, Tredium will provide its claims platform to support accurate and reliable processing for Scripius and the customers it serves. Scripius empowers health plans, health systems, and self-funded employers to better manage rising pharmacy cos.
Pacific Bay Adopts Semi-Annual Reporting
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Pacific Bay Minerals Ltd. (TSXV: PBM) ("Pacific Bay" or the "Company") reports that the Company is adopting semi-annual financial reporting in place of quarterly reporting, effective for the three-month interim period ending (Q1 2026 period end date).
PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story
Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceutical-grade drug candidates, today provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand.
Aurwest Resources Announces Execution of Definitive Agreement on Weaver Lake Gold Project
Calgary, Alberta – TheNewswire - April 14, 2026 – Aurwest Resources Corporation (“ Aurwest ” or the “ Company ”) ( CSE: AWR ) is pleased to announce that the Company has entered into a Definitive Option and Joint Venture Agreement (the “ Agreement ”) with Pacific Bay Minerals Ltd. (TSXV: PBM) whereby Aurwest has acquired an option to earn, subject to the satisfaction of conditions, an undivided interest of up to 50% in the Weaver Gold gold/silver property (the “ Transaction ”) in British Columbia. Transaction Summary
Psyence Biomedical Shares Set to Reverse Split on Tuesday, January 20th (NASDAQ:PBM)
Psyence Biomedical Ltd. (NASDAQ: PBM) shares are set to reverse split on the morning of Tuesday, January 20th. The 1-6.25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, January 19th. Psyence Biomedical Stock Performance Shares of NASDAQ: PBM opened at $0.67
Psyence Biomedical Ltd. (NASDAQ:PBM) Short Interest Update
Psyence Biomedical Ltd. (NASDAQ: PBM - Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totaling 312,062 shares, a growth of 205.2% from the November 30th total of 102,238 shares. Approximately 17.3% of the company's stock are short sold. Based on an
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company's 2025 achievements and outlining its strategic vision for 2026.
Psyence Biomedical (NASDAQ:PBM) Trading Down 2.5% – Should You Sell?
Shares of Psyence Biomedical Ltd. (NASDAQ: PBM - Get Free Report) dropped 2.5% during mid-day trading on Tuesday. The stock traded as low as $1.51 and last traded at $1.58. Approximately 115,404 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 1,164,693 shares. The stock had previously closed
Curaechoice Selects CVS Caremark at its PBM
All Active Curaechoice Members and their Families Will Have Access to CVS Pharmacies Nationwide Starting January 1 All Active Curaechoice Members and their Families Will Have Access to CVS Pharmacies Nationwide Starting January 1
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
Arbli ™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life
Pacific Bay Warrant Extension Not Proceeding
Vancouver, British Columbia--(Newsfile Corp. - August 1, 2025) - Reagan Glazier, President & CEO, Pacific Bay Minerals Ltd. (TSXV: PBM) ("Pacific Bay" or, the "Company") reports that the proposed extension of warrants announced July 8th, 2025 will not be proceeding.
CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?
CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.
CVS Sues Arkansas Over Law Banning PBM Ownership Of Pharmacies
CVS Health Thursday sued the state of Arkansas, trying to thwart a law the healthcare company said would lead to the closure of all 23 CVS drugstores in the state.
CVS Health Stock Rallies 38% in May: Is it a Buy Amid PBM Pressure?
CVS' pharmacy segment continues to lead the industry, processing over 1.7 billion prescriptions annually while delivering high medication adherence.
CVS's stock soars after a big profit beat, continued improvement in PBM business
CVS's stock soared toward a three-month high after its quarterly profit beat expectations by the widest margin in more than four years.
CVS's Sell-Off May Be Overblown
CVS plunged to $49, trading at a forward P/E of 8-9x, well below its 16x historical average. PBM segment contributes 46% of CVS income; fears of reform impact led to significant market overreaction. A 25% PBM profitability cut reduces EPS to ~$4, implying a fair value of $60 (with a P/E of 15x).
CVS Health Hits 11-Year Low; PBM Legislation Could Slash Earnings By 50%, Says Analyst
New legislation targeting pharmacy benefit managers (PBMs) could cut CVS Health earnings in half. CVS stock fell, along with UnitedHealth and Cigna.
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context has been listed on the Australian New Zealand Clinical Trials Registry (“ANZCTR”), under registration number 12624000449538p.
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd. (“Psyence Australia”), has entered into a partnership with Fluence , a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial. The trial will explore the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for the treatment of Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.